Stigmasterol sensitizes endometrial cancer cells to chemotherapy by repressing Nrf2 signal pathway

BACKGROUND: Chemoresistance reduces the 5-year survival rate of endometrial cancer patient, which is the current major obstacle for cancer therapy. Increasing evidence state that Nrf2 contributes to chemoresistance in several kinds of cancer. However, its role in endometrial cancer cells remains unc...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Hong, Zhu, Dan, Bai, Mingzhu, Chen, Huifen, Yan, Shihuan, Yu, Jing, Zhu, Huiting, Zheng, Wenxin, Fan, Guorong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7541302/
https://www.ncbi.nlm.nih.gov/pubmed/33041661
http://dx.doi.org/10.1186/s12935-020-01470-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7541302/
https://www.ncbi.nlm.nih.gov/pubmed/33041661
http://dx.doi.org/10.1186/s12935-020-01470-x

Ejemplares similares